Treatment of CLL cells with the cell-permeable phospho-peptide EGQY*EEIP has been shown to preferentially bind the SH2 domain of Lck vs Lyn due to the specificity of the YEEI sequence, which prevents activation of Lck’s catalytic domain [21]. This evidence concerns the gene LYN and B-cell chronic lymphocytic leukemia.